BridgeBio Pharma (BBIO) Q1 FY26 earnings call

BridgeBio Pharma delivered a strong first quarter, driven by exceptional commercial momentum for Attruby, which is now a leading brand in the ATTR-CM market. The company also highlighted significant progress across its late-stage pipeline, including rapid regulatory submissions and positive clinical data for LGMD2I, ADH1, and achondroplasia. Management announced a $500 million share repurchase program, emphasizing a commitment to capturing shareholder value and leveraging a robust balance sheet.